Clinical Trials
45 trialsAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Aragon Pharmaceuticals, Inc.
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
S1216
SWOG Cancer Research Network
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
Radiation Therapy Oncology Group
PCS III
Université de Sherbrooke
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
DART
Canadian Cancer Trials Group
SPA
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
UNICANCER
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
SWOG Cancer Research Network
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Radiation Therapy Oncology Group
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Radiation Therapy Oncology Group
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
M.D. Anderson Cancer Center
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
SWOG Cancer Research Network
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Schiffler Cancer Center
Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
Karolinska University Hospital
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
AstraZeneca
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
University of British Columbia
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
Ferring Pharmaceuticals
Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Rising PSA
Sanofi
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Ferring Pharmaceuticals
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer
M.D. Anderson Cancer Center
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Bicalutamide (Casodexâ„¢) Versus Placebo in Patients With Early Prostate Cancer
AstraZeneca
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
AstraZeneca
Capri
AstraZeneca
SPCG6
AstraZeneca
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
Speciality European Pharma Limited